Kisspeptin-10 and PT-141 are often listed side by side, as if they were two options for the same purpose. They act on different receptors, in different parts of the body’s signaling architecture, and they sit on opposite sides of a regulatory line. PT-141, as bremelanotide, is an FDA-approved prescription drug with a narrowly defined label. Kisspeptin-10 is an investigational peptide with no approved product anywhere in the world.
The pairing makes some sense on the surface: both are short peptides, and both are studied in relation to reproduction-linked biology. But PT-141 acts on melanocortin receptors in the central nervous system, while Kisspeptin-10 acts on KISS1R, the receptor that sits upstream of the hormonal cascade controlling the reproductive axis. Those are separate systems, and evidence for one says nothing about the other.
The argument of this post is that the two compounds should be compared on mechanism, evidence and regulatory status, not treated as alternatives. The sections below set out what each one is, what the FDA approval for bremelanotide actually covers, what human research on kisspeptin has and has not shown, and what is known about the safety of each.
Two Peptides, Two Receptor Systems
| PT-141 (bremelanotide) | Kisspeptin-10 | |
|---|---|---|
| What it is | Synthetic cyclic peptide; melanocortin receptor agonist | 10-amino-acid fragment of the endogenous kisspeptin peptides |
| Primary receptor(s) | Melanocortin receptors (MC4R most discussed; MC1R relevant to pigmentation) | KISS1R (also called GPR54) |
| Where it acts | Central nervous system pathways | Hypothalamus, upstream of GnRH; the top of the HPG axis |
| Hormonal effect | Not designed to act through the reproductive hormone cascade | Stimulates LH and FSH release via GnRH |
| Regulatory status (U.S.) | FDA-approved as Vyleesi (2019) for one defined indication | Not approved in any country; FDA recommended against compounding use |
| Human evidence | Two 24-week phase 3 trials, 1,247 participants | Small, short physiological studies, about 300 participants in total |
PT-141 (Bremelanotide): A Melanocortin Receptor Agonist
Bremelanotide is a synthetic peptide that activates melanocortin receptors, a family of five receptor subtypes (MC1R to MC5R) that respond to melanocyte-stimulating hormones. MC4R, expressed in the brain, is the subtype most often discussed in connection with its central effects. MC1R, expressed on melanocytes, explains one of its documented side effects, focal skin pigmentation.
The FDA label is candid about mechanism. It states that bremelanotide activates melanocortin receptors but that the mechanism behind its clinical effect is unknown (FDA prescribing information, via MedLibrary). What is clear is that it works through a receptor system distinct from the reproductive hormone axis. It is not a gonadotropin-releasing compound, and its approval did not rest on hormone measurements.
What the FDA Approval Covers
The FDA approved Vyleesi (bremelanotide) on June 21, 2019 (FDA approval letter, NDA 210557). Its indication is narrow and specific: premenopausal women with acquired, generalized hypoactive sexual desire disorder that is not due to a co-existing medical or psychiatric condition, problems in the relationship, or the effects of a medication or drug substance.
The label is equally specific about what is excluded. Vyleesi is not indicated for postmenopausal women, for men, or to enhance sexual performance (Optum Rx approval summary).
The approval was based on two 24-week, randomized, double-blind, placebo-controlled trials in 1,247 premenopausal women with the labeled condition. That evidence establishes the drug’s benefit–risk balance for that population under prescription. It does not establish effectiveness or safety in any other population, for any other use, or for any non-prescription product sold under the PT-141 name.
PT-141 Safety in the FDA Label
Because bremelanotide is approved, its safety profile is documented in unusual detail for a peptide. The figures below come from the pooled phase 3 trials in the labeled population (FDA prescribing information; Drugs.com label copy).
| Effect | What the label reports |
|---|---|
| Nausea | 40% vs 1% with placebo; 13% needed anti-emetic medication; 8% left the trials because of it. Most frequent after the first dose. |
| Flushing | About 20% vs under 1% with placebo |
| Headache | About 11% vs 2% with placebo |
| Blood pressure and heart rate | Transient rise of up to 6 mmHg systolic and 3 mmHg diastolic, peaking 2–4 hours after a dose, with heart rate falling by up to 5 beats per minute; usually back to baseline within 12 hours |
| Focal hyperpigmentation | 1% in phase 3 trials; 38% in a separate study with daily dosing over 8 days. Affects face, gums and breasts; not always reversible; more likely with darker skin |
| Discontinuation for adverse reactions | 18% vs 2% with placebo |
Contraindications and limits. Bremelanotide is contraindicated in people with uncontrolled hypertension or known cardiovascular disease, and the label advises against use in those at high cardiovascular risk. It can reduce the effectiveness of oral naltrexone. The label also caps how often it may be used, because more frequent use increases blood pressure exposure and the risk of pigmentation.
Kisspeptin-10: A Fragment Upstream of the HPG Axis
Kisspeptins are a family of peptides produced from a single gene, KISS1. Its 145-amino-acid precursor protein is cut into several active forms, including kisspeptin-54, -14, -13 and -10. All of them share the same final ten amino acids, which is the sequence of Kisspeptin-10 (Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2) (FDA evaluation of kisspeptin-10, 2024).
KISS1R and GnRH. Kisspeptins activate KISS1R (also called GPR54), a receptor concentrated in the hypothalamus. Kisspeptin-producing neurons project to the neurons that release gonadotropin-releasing hormone (GnRH), and their signaling helps set the timing of GnRH pulses.
The HPG axis. The hypothalamic–pituitary–gonadal axis is the hormonal chain that regulates reproduction. GnRH from the hypothalamus prompts the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn act on the testes or ovaries to produce sex hormones. Those hormones feed back to dampen the signal further up the chain, a feedback principle similar to the one discussed in our comparison of GH secretagogues and exogenous growth hormone. Kisspeptin sits at the top of this chain, upstream of GnRH. Mice lacking a functional KISS1R gene show abnormal sexual development and low gonadotropin levels.
Pharmacology. Kisspeptin-10 is cleared very quickly, with a plasma half-life of about four minutes in humans. Continuous high-dose exposure in animals and humans produces tachyphylaxis: an initial LH surge followed by a return to baseline as the receptor desensitizes.
What Human Kisspeptin Research Shows
Human studies of kisspeptin-10 are physiological rather than therapeutic. Most measure how LH and FSH respond to single doses or short infusions in healthy volunteers, or use kisspeptin as a probe of GnRH neuron function in people with congenital hypogonadotropic hypogonadism. In those patients, kisspeptin-10 often produced no LH response at doses that worked in healthy people. In healthy men, kisspeptin-10 raised LH and FSH but did not consistently raise testosterone.
The brain-imaging studies most often cited for kisspeptin used a different molecule. A 2017 study in 29 healthy young men found that kisspeptin infusion enhanced activity in limbic brain regions during viewing of emotional and relationship-related images, alongside an expected rise in LH, with no change in testosterone or cortisol (Comninos et al., J Clin Invest, 2017). Later small randomized studies by the same Imperial College group used kisspeptin-54, the 54-amino-acid isoform, given intravenously over 75 minutes. These are proof-of-concept neuroimaging studies in small samples. They do not establish any therapeutic effect, and they do not provide evidence about kisspeptin-10 specifically.
Kisspeptin-10 Safety: What Is and Isn’t Known
The FDA’s 2024 evaluation of kisspeptin-10, prepared for its Pharmacy Compounding Advisory Committee, is the most thorough public review of its safety record (FDA evaluation). Its conclusions are best grouped by evidence type.
Human data. About 300 people have received kisspeptin-10 across small studies. The longest continuous infusion lasted 24 hours, no published study assessed repeated dosing beyond a single day, no study used intramuscular injection, and only one gave a single subcutaneous dose. Acute intravenous use raised no major safety concerns, but the data cannot speak to longer-term exposure.
Immunogenicity and aggregation. FDA concluded that injectable kisspeptin-10 may pose a significant risk of immune reactions, potentially amplified by aggregation and peptide-related impurities. Because the synthetic peptide is identical to the body’s own sequence, antibodies formed against it could in principle cross-react with endogenous kisspeptin. No study has formally tested its immunogenicity. Why aggregation and impurities matter for any peptide is covered in our guide to reading a peptide certificate of analysis.
Cardiovascular findings (preclinical). In human vascular cells and in atherosclerosis-prone ApoE-knockout mice, kisspeptin-10 promoted inflammatory and pro-atherosclerotic changes that were blocked by a KISS1R antagonist (Sato et al., 2017, as reviewed by FDA). FDA noted that the cell-culture concentrations were roughly 7,400 times higher than plasma levels in human studies, and that the clinical relevance is unknown.
Reproductive tissue findings (animal). FDA identified no formal reproductive toxicity studies. Separately, a 2022 study reported dose-dependent Leydig cell degeneration and reduced testosterone in prepubertal rats given repeated kisspeptin-10 (Ramzan et al., Protein Pept Lett, 2022). These are findings in immature animals under specific dosing conditions and have not been studied in humans.
Regulatory status. FDA recommended against adding kisspeptin-10 to the list of substances that may be used in pharmacy compounding, and it remains in Category 2, the category for substances raising significant safety concerns. It was not among the peptides FDA moved out of Category 2 in April 2026 (FDA Category 2 safety risks list).
Why They Are Not Interchangeable
- Different receptors. Melanocortin receptors and KISS1R belong to different signaling systems with different natural ligands.
- Different levels of the system. Bremelanotide acts on central melanocortin pathways; Kisspeptin-10 acts at the top of the reproductive hormone cascade and works through LH and FSH.
- Different evidence. One has two large phase 3 trials in a defined population; the other has small, short physiological studies, and its best-known brain research used a different isoform.
- Different regulatory standing. One is an approved prescription drug for a single indication; the other is investigational everywhere.
- No transfer of evidence. Approval of bremelanotide for one population establishes nothing about other populations, and nothing about kisspeptin.
Frequently Asked Questions
Q1: What is the difference between Kisspeptin-10 and PT-141?
Direct Answer: PT-141 (bremelanotide) activates melanocortin receptors in the central nervous system and is FDA-approved for one indication, while Kisspeptin-10 activates KISS1R at the top of the reproductive hormone axis and is an investigational compound.
- Receptors: Melanocortin receptors versus KISS1R.
- Pathway: Central melanocortin signaling versus GnRH, LH and FSH.
- Status: Approved prescription drug versus research compound.
Q2: What is PT-141 FDA-approved for?
Direct Answer: Vyleesi (bremelanotide) was approved in June 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder that is not caused by another medical, psychiatric, relationship or medication factor.
- Not indicated: For postmenopausal women or men.
- Not indicated: To enhance sexual performance.
- Evidence base: Two 24-week trials in 1,247 premenopausal women.
Q3: What are the main side effects in PT-141’s label?
Direct Answer: Nausea is the most common, reported in 40% of participants in the phase 3 trials versus 1% on placebo, followed by flushing, injection site reactions and headache. Transient blood pressure rises and focal hyperpigmentation are listed warnings.
- Blood pressure: Up to 6/3 mmHg rise, with a small fall in heart rate.
- Pigmentation: Not always reversible.
- Contraindicated: In uncontrolled hypertension or known cardiovascular disease.
Q4: Is Kisspeptin-10 approved anywhere?
Direct Answer: No. FDA found no approved product containing kisspeptin-10 in any country, recommended against its use in pharmacy compounding in 2024, and it remains on FDA’s Category 2 list of substances raising significant safety concerns.
- Pharmacopeias: No monograph in the U.S., European or Japanese pharmacopeias.
- FDA concern: Immunogenicity, aggregation and impurities.
- April 2026: Not among the peptides removed from Category 2.
Q5: Did human brain-imaging studies use Kisspeptin-10?
Direct Answer: The most-cited human neuroimaging studies used kisspeptin-54, the longer isoform, given by intravenous infusion. They do not provide direct evidence about kisspeptin-10.
- Design: Small, randomized, placebo-controlled crossover studies.
- Measures: Brain activity on fMRI and hormone levels.
- Limits: Proof-of-concept only; no established therapeutic effect.
Q6: What safety concerns have been raised for Kisspeptin-10?
Direct Answer: FDA has flagged potential immunogenicity with injectable forms, and preclinical studies have reported pro-atherosclerotic effects in mice and cell culture and Leydig cell changes in immature rats. Long-term human safety has not been studied.
- Human exposure: About 300 people, mostly single doses or infusions up to 24 hours.
- Atherosclerosis data: Cell and mouse studies; clinical relevance unknown.
- Reproductive tissue data: Prepubertal rats only.
An Approved Drug and a Research Peptide
The comparison between Kisspeptin-10 and PT-141 is ultimately a comparison between two different kinds of object. Bremelanotide is a prescription medicine whose benefits and risks have been weighed by a regulator for one defined population, with its side effects documented in a label. Kisspeptin-10 is a research peptide that sits at the head of the reproductive hormone axis, with a small, short-term human record, unresolved preclinical safety questions and no approval anywhere.
They are linked by a shared interest in how the brain and endocrine system interact, not by a shared mechanism. Research on either compound is best served by keeping those distinctions explicit: the receptor, the pathway, the isoform actually studied, and the population and regulatory context in which any evidence was generated.
Ready to Advance Your Research?
Browse our catalog of verified research peptides, sourced and shipped exclusively within Canada. COAs available on request.
Disclaimer: All Peptide Wave products are intended strictly for laboratory research use only. Not approved for, nor intended for, human or veterinary consumption.
